Actrapid® (insulin human rDNA)

Esperoct®  (turoctocog alfa pegol)

Fiasp® (fast-acting insulin aspart)

GlucaGen® HypoKit (glucagon rys)

Insulatard® (insulin human rDNA)

Kilofem® (estradiol/norethisterone)

Kilovance® (estradiol/norethisterone acetate)

Levemir® (insulin detemir)

Norditropin® (somatropin (recombinant DNA origin))

NovoEight® (turoctocog alfa)

Novofem® (estradiol/norethisterone)

NovoThirteen® (catridecacog) 

NovoMix® 30 (biphasic insulin aspart)

NovoRapid® (insulin aspart)

NovoSeven® (eptacog alfa activated)

Ozempic®  (semaglutide)

Refixia®  (nonacog beta pegol)

Rybelsus®  (semaglutide tablets)

Saxenda® (liraglutide injection 3mg)

Tresiba® (insulin degludec)

Trisequens® (estradiol/norethisterone acetate)

Vagifem® (estradiol)

Victoza® (liraglutide)

Wegovy®  (semaglutide injection)

Xultophy® (insulin degludec/liraglutide)

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.  

Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored for training purposes.

 This medicine is subject to additional safety monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk/ for how to report side effects.

This page is intended for members of the UK public

 

PromoMats ID: UK22NNG00138 | Date of prep November 2022